机构

• 上海药物研究所 [6]
• 自动化研究所 [1]

采集方式

• OAI收割 [7]

内容类型

• 期刊论文 [7]

发表日期

• 2020 [7]

学科主题

筛选

浏览/检索结果: 共7条，第1-7条 帮助 限定条件 发表日期：2020     条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 9 作者:  Dai, Meng-di;  Wang, Yue-liang;  Fan, Jun;  Dai, Yang;  Ji, Yin-chun   |  收藏  |  浏览/下载：66/0  |  提交时间：2021/05/24 receptor tyrosine kinase  FGFR inhibitor  DW14383  antitumor activity   Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients 期刊论文  OAI收割 BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 页码: 13 作者:  Liu, Lu;  Wang, Qian;  Xie, Cen;  Xi, Ning;  Guo, Zitao   |  收藏  |  浏览/下载：42/0  |  提交时间：2020/12/24 drug–  drug interaction  gefitinib  ningetinib  transporters   Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function 期刊论文  OAI收割 MOLECULAR CANCER THERAPEUTICS, 2020, 卷号: 19, 期号: 11, 页码: 2340-2352 作者:  Jin, Rui;  Liu, Liang;  Xing, Yun;  Meng, Tao;  Ma, Lanping   |  收藏  |  浏览/下载：61/0  |  提交时间：2020/12/24 Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 10 作者:  Zhang, Xiao-tuan;  Hu, Xiao-bei;  Wang, Han-lin;  Kan, Wei-juan;  Xu, Lei   |  收藏  |  浏览/下载：75/0  |  提交时间：2020/12/24 DLBCL  BTK inhibitor  ibrutinib resistance  UPR  TUDCA  2-DG   Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文  OAI收割 JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026 作者:  Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong   |  收藏  |  浏览/下载：82/0  |  提交时间：2020/12/24 Alflutinib  NSCLC  EGFR T790M mutation  Efficacy  Safety   Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2020, 卷号: 41, 期号: 3, 页码: 415-422 作者:  Lai, Meng-zhen;  Song, Pei-ran;  Dou, Dou;  Diao, Yan-yan;  Tong, Lin-jiang   |  收藏  |  浏览/下载：14/0  |  提交时间：2020/07/01 B cell receptor  Bruton's tyrosine kinase  ibrutinib  small-molecule inhibitor  B cell malignancies   CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study 期刊论文  OAI收割 FRONTIERS IN ONCOLOGY, 2020, 卷号: 10, 页码: 9 作者:  Li, Hailin;  Zhang, Rui;  Wang, Siwen;  Fang, Mengjie;  Zhu, Yongbei   |  收藏  |  浏览/下载：51/0  |  提交时间：2020/04/07 computed tomography  radiomics  non-small-cell lung cancer  tyrosine kinase inhibitor resistance  anaplastic lymphoma kinase